Colgate-Palmolive (NYSE: CL) reported Q4 EPS of $0.91, $0.01 better than the analyst estimate of $0.90. Revenue for the quarter came in at $4.94 billion versus the consensus estimate of $5.03 billion.

GUIDANCE

Full Year 2025 Guidance

Based on current spot rates:

The Company expects net sales to be roughly flat, including a mid-single-digit negative impact from foreign exchange.
The Company expects organic sales growth to be within its long-term targeted range of 3% to 5%, including the impact of the planned exit from private label pet nutrition over the course of 2025.
On a GAAP basis, the Company expects gross profit margin expansion with advertising investment flat to up slightly on both a dollar basis and as a percent to sales and mid-single-digit earnings-per-share growth.
On a non-GAAP (Base Business) basis, the Company expects gross profit margin expansion with advertising investment flat to up slightly on both a dollar basis and as a percent to sales and low to mid-single-digit earnings-per-share growth.

For earnings history and earnings-related data on Colgate-Palmolive (CL) click here.